Johnson & Johnson: Stable Growth and Upside Potential in the Healthcare Sector

# Johnson & Johnson Stock Analysis: Performance, Dividends & Analyst Outlook in 2025 Discover the latest financial insights on Johnson & Johnson (JNJ) as of August 2025, with shares trading at approximately $165, near the upper end of its 52-week range. This episode examines JNJ's impressive Q2 results showing 5.8% revenue growth to $24 billion and EPS of $2.77, exceeding analyst expectations. Learn why major firms like RBC and Barclays have raised price targets to $185 and $176 respectively, reflecting a consensus "moderate buy" rating. We also analyze JNJ's attractive 3%+ dividend yield with its upcoming ex-dividend date, strong cash flow position, and what the recent above-average trading volume of 11 million shares indicates about investor sentiment. Perfect for investors interested in blue-chip healthcare stocks with stable growth potential and income generation. For more http://www.quietplease.ai Stock up on these deals https://amzn.to/3QFpYIX This content was created in partnership and with the help of Artificial Intelligence AI.